GMABGenmabSigning up patients
Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer
Endometrial Cancer · Recurrent or Progressive Endometrial Cancer
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 660 (planned)
- Started
- Nov 28, 2025
- Main results expected
- Aug 2029
- Fully finished
- Nov 2029
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Progression-free Survival (PFS) per Response Criteria in Solid Tumors (RECIST) v1.1, as Determined by Blinded Independent Central Review (BICR)
Measured over: Up to approximately 3 years
Overall Survival (OS)
Measured over: Up to approximately 3 years
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT07166094 · record last updated 2026-11-03 · checked 2026-11-09 15:47 UTC